Cyberknife radiosurgery for melanoma that has spread to the brain
Observes how focused radiotherapy works in adults with melanoma spread to the brain.
Plain-language title generated from the registry record
Registry title: MELanoma Brain Metastasis Treated With CYberknife
Key facts
- Where
- Milan, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma that has spread to the brain and can be treated with stereotactic radiotherapy.
- Age
- Older than 18 years
- Sex
- All sexes can join.
- Disease stage
- Melanoma brain metastases found on brain MRI/CT that can be treated with stereotactic radiotherapy.
- Earlier treatment
- No earlier whole-brain radiotherapy and no surgery to remove brain metastases. Immunotherapy or targeted therapy is allowed, at the same time as the radiotherapy or not.
Main reasons for not taking part
- Cancer spread into the membranes around the brain (leptomeningeal infiltration)
- Earlier whole-brain radiotherapy
- Earlier surgery to remove brain metastases
- Non-cutaneous melanoma, for example uveal melanoma
Read by machine on 9 November 2026.
Where in Italy
- European Institute of Oncology, MilanMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- European Institute of Oncology
- Trial code
- NCT07691255
- Record updated
- 10 September 2026
- Original description
Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life.Read full original descriptionShow less
Impact of Stereotactic Radiosurgery With Cyberknife In Patients With Brain Melanoma Metastases In The Era Of New Drugs
Melanoma is a type of cancer that can spread to the brain, making the disease harder to treat and worsening both survival and quality of life.
In recent years, treatments have improved significantly thanks to advances in surgery, radiotherapy, immunotherapy, and targeted therapy. These new treatments have greatly increased survival rates for patients with metastatic melanoma.
This study focuses on stereotactic radiosurgery, a highly precise form of radiotherapy used to treat brain metastases. Researchers want to better understand how this treatment works when combined with immunotherapy or targeted therapy, and whether the timing and sequence of treatments can improve outcomes.
Between 2026 and 2028, patients treated at the IEO for melanoma brain metastases will be observed and their clinical data collected. The goal is to improve future treatment strategies and help doctors choose the best therapeutic approach for each patient.
Inclusion: Age > 18; Written informed consent for treatment and research purposes; Melanoma Brain Metastases (MBM) diagnosed with brain MRI/CT; MBM treatable with stereotactic radiotherapy; Systemic therapy (immunotherapy, target therapy, or both) is allowed, as concurrent or non-concurrent treatment with stereotactic radiotherapy.
Exclusion: Previous whole-brain radiotherapy or surgical removal of brain metastases; Leptomeningeal neoplastic infiltration; Patients with histological diagnosis of non-cutaneous melanoma (e.g. uveal melanoma).